New role of microRNA: Carcinogenesis and clinical application in cancer

Acta Biochimica et Biophysica Sinica

Volumn 43, Issue 11, 2011, Pages 831-839

  Zhao, Luqing ^a,b,c   Chen, Xue ^a,b,c   Cao, Ya ^a,b,c  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b BEIJING HOSPITAL   (China)

^c Central South University   (China)

Author keywords

cancer clinical application; cancer stem cells; carcinogenesis; epithelialmesenchymal transition; invasion and migration; microRNA

Indexed keywords

BIOLOGICAL MARKER; DIAGNOSTIC AGENT; MICRORNA;

BLOOD; CANCER INVASION; CANCER STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; HUMAN; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY; REVIEW;

BIOLOGICAL MARKERS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 80455123713     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmr080     Document Type: Review

References (110)

1. Spizzo R, Nicoloso MS, Croce CM and Calin GA. SnapShot: MicroRNAs in cancer. Cell 2009, 137:586.
2. Filipowicz W, Bhattacharyya SN and Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008, 9:102-114.
3. Gregory RI, Chendrimada TP, Cooch N and Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005, 123:631-640.
4. Liu X, Fortin K and Mourelatos Z. MicroRNAs: biogenesis and molecular functions. Brain Pathol 2008, 18:113-121.
5. Bushati N and Cohen SM. MicroRNA functions. Annu Rev Cell Dev Biol 2007, 23:175-205.
6. Felekkis K, Touvana E, Stefanou Ch and Deltas C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia 2010, 14:236-240.
7. Pang Y, Young CY and Yuan H. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin 2010, 42:363-369.
8. Israel A, Sharan R, Ruppin E and Galun E. Increased microRNA activity in human cancers. PLoS One 2009, 4:e6045.
9. Wu M, Jolicoeur N, Li Z, Zhang L, Fortin Y, L'Abbe Denis and Yu Z, et al. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis 2008, 29:1710-1716.
10. Kumar MS, Lu J, Mercer KL, Golub TR and Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genet 2007, 39:673-677.
11. Aurora EK and Frank JS. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
12. Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y and Libutti SK, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009, 23:2152-2165.
13. Kalluri R and Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428.
14. Chaffer CL, Thompson EW and Williams ED. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 2007, 185:7-19.
15. Douglas SM, Susan MF and Heide LF. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010, 15:117-134.
16. Gavert N and Ben-Ze'ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 2008, 14:199-209.
17. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A and Calin G, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009, 15:5060-5072.
18. Hurteau GJ, Carlson JA, Spivack SD and Brock GJ. Overexpression of the microRNA hsa-miR-208c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007, 67:7972-7976.
19. Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F and Martinvalet D, et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 2009, 4:e7181.
20. Korpal M, Lee ES, Hu G and Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008, 283:14910-14914.
21. Park SM, Gaur AB, Lengyel E and Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22:894-907.
22. Chen J, Wang L, Matyunina LV, Hill CG and McDonald JF. Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol 2011, 121:200-205.
23. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naga IM, Schwarz JK and Mutch DG, et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 2009, 114:457-464.
24. Ozcan S. MiR-30 family and EMT in human fetal pancreatic islets. Islets 2009, 1:283-285.
25. Joglekar MV, Patil D, Joglekar VM, Rao GV, Reddy DN, Mitnala S and Shouche Y, et al. The miR-30 family microRNAs confer epithelial phenotype to human pancreatic cells. Islets 2009, 1:137-147.
26. Wang B and Jacob ST. Role of cancer stem cells in hepatocarcinogenesis. Genome Med 2011, 3:11.
27. Soltanian S and Matin MM. Cancer stem cells and cancer therapy. Tumour Biol 2011, 32:425-440.
28. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL and Visvader J, et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
29. Rangwala F, Omenetti A and Diehl AM. Cancer stem cells: repair gone awry? J Oncol 2011, 2011:465343.
30. Takebe N, Harris PJ, Warren RQ and Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011, 8:97-106.
31. Bolós V, Blanco M, Medina V, Aparicio G, Díaz-Prado S and Grande E. Notch signalling in cancer stem cells. Clin Transl Oncol 2009, 11:11-19.
32. Medina V, Calvo MB, Díaz-Prado S and Espada J. Hedgehog signalling as a target in cancer stem cells. Clin Transl Oncol 2009, 11:199-207.
33. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, Mclntyre D, Honess D and Madhu B, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
34. Gould T and Missailidis S. Targeting the Hedgehog pathway: the development of cyclopamine and the development of anti-cancer drugs targeting the Hedgehog pathway. Mini Rev Med Chem 2011, 11:200-213.
35. Kelleher FC. Hedgehog signalling and therapeutics in pancreatic cancer. Carcinogenesis 2011, 32:445-451.
36. O'Toole SA, Swarbrick A and Sutherland RL. The Hedgehog signalling pathway as a therapeutic target in early breast cancer development. Expert Opin Ther Targets 2009, 13:1095-1103.
37. Navarro A and Monzo M. MicroRNAs in human embryonic and cancer stem cells. Yonsei Med J 2010, 51:622-632.
38. Zahnow CA and Baylin SB. Epigenetic networks and miRNAs in stem cells and cancer. Mol Cell 2010, 39:661-663.
39. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L and Xiang D, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009, 4:e6816.
40. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N and Bentwich Z, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007, 26:731-743.
41. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D and Xu L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008, 8:266.
42. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ and Molven A. Expression of the 'stem cell marker' CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 2008, 8:48.
43. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H and Patrawala L, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011, 17:211-215.
44. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J and Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006, 5:483-493.
45. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W and Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007, 67:8433-8438.
46. Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K and Rankin-Gee EK, et al. Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011, 30:1470-1480.
47. Misawa A, Katayama R, Koike S, Tomida A, Watanabe T and Fujita N. AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. Oncol Res 2010, 19:23-33.
48. Barh D, Malhotra R, Ravi B and Sindhurani P. Microrna let-7: an emerging next-generation cancer therapeutic. Curr Oncol 2010, 17:70-80.
49. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C and Huang Y, et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
50. Bockhorn M, Jain RK and Munn LL. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol 2007, 8:444-448.
51. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3:453-458.
52. Langley RR and Fidler IJ. The seed and soil hypothesis revisited - the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011, 128:2527-2535.
53. Zhao XL, Sun T, Che N, Sun D, Zhao N, Dong XY and Gu Q, et al. Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator twist1. J Cell Mol Med 2011, 15:691-700.
54. Lin CY, Tsai PH, Kandaswami CC, Lee PP, Huang CJ, Hwang JJ and Lee MT. Matrix metalloproteinase-9 cooperates with transcription factor Snail to induce epithelial-mesenchymal transition. Cancer Sci 2011, 102:815-27.
55. Orlichenko LS and Radisky DC. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis 2008, 25:593-600.
56. Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K and Enokida H, et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol 2011, 38:1093-1101.
57. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D and Teruya-Feldstein J, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010, 12:247-256.
58. Tan HX, Wang Q, Chen LZ, Huang XH, Chen JS, Fu XH and Cao LQ, et al. MicroRNA-9 reduces cell invasion and E-cadherin secretion in SK-Hep-1 cell. Med Oncol 2010, 27:654-660.
59. Khew-Goodall Y and Goodall GJ. Myc-modulated miR-9 makes more metastases. Nat Cell Biol 2010, 12:209-211.
60. Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P and Wood CG, et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010, 29:5724-5728.
61. Uchida N. MicroRNA-9 controls a migratory mechanism in human neural progenitor cells. Cell Stem Cell 2010, 6:294-296.
62. Yang CC, Hung PS, Wang PW, Liu CJ, Chu TH, Cheng HW and Lin SC. miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. J Oral Pathol Med 2011, 40:397-404.
63. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y and Dequchi T, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008, 377:114-119.
64. Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J, Zhao JJ and Mao SS, et al. miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer 2011, 117:2842-2852.
65. Le XF, Merchant O, Bast RC and Calin GA. The roles of microRNAs in the cancer invasion-metastasis cascade. Cancer Microenviron 2010, 3:137-147.
66. Fan X, Liu Y, Jiang J, Ma Z, Wu H, Liu T and Liu M, et al. miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells. Acta Biochim Biophys Sin 2010, 42:318-324.
67. Swarup V and Rajeswari MR. Circulating (cell-free) nucleic acids-a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 2007, 581:795-799.
68. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N and Benjamin H, et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3:e3148.
69. Cortez MA and Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009, 9:703-711.
70. Yu DC, Li QG, Ding XW and Ding YT. Circulating microRNAs: potential biomarks for cancer. Int J Mol Sci 2011, 12:2055-2063.
71. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T and Beissbarth T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011, 128:608-616.
72. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010, 251:499-505.
73. Heneghan HM, Miller N and Kerin MJ. Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol 2010, 28:e573-574.
74. Brase JC, Wuttig D, Kuner R and Sültmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010, 9:306.
75. Reid G, Kirschner MB and van Zandwijk N. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2010, doi: 10.1016/j.critrevonc.2010.11.004. (Epub ahead of print).
76. Qu KZ, Zhang K, Li H, Afdhal NH and Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011, 45:355-360.
77. Zen K and Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2010, doi: 10.1002/med.20215. (Epub ahead of print).
78. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB and Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 2010, 5:e13735.
79. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K and Guo J, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
80. Foss KM, Sima C, Ugolini D, Neri M, Allen KE and Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 2011, 6:482-488.
81. Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010, 127:118-126.
82. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J and Poon TC, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58:1375-1381.
83. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K and Banham AH, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672-675.
84. Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K and Kuroda M. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009, 4:e5532.
85. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL and Peterson A, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105:10513-10518.
86. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H and Simko J, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011, 71:550-560.
87. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT and Koong AC. Circulating miR-210 as a Novel Hypoxia Marker in pancreatic cancer. Transl Oncol 2010, 3:109-113.
88. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL and Frazier ML, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009, 2:807-813.
89. Zhu Z, Gao WT, Qian ZY and Miao Y. Genetic variation of miRNA sequence in pancreatic cancer. Acta Biochim Biophys Sin 2009, 41:407-413.
90. Weiler J, Hunziker J and Hall J. Anti-microRNA oligonucleotides (AMOs): ammunition to target microRNAs implicated in human disease? Gene Ther 2006, 13:496-502.
91. Prakash TP, Kawasaki AM, Wancewicz EV, Shen L, Monia BP, Ross BS and Bhat B, et al. Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2- oxoethyl]-and 2'-O-methoxyethyl-modified antisense oligonucleotides. J Med Chem 2008, 51:2766-2776.
92. Stenvang J, Silahtaroglu AN, Lindow M, Elmen J and Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol 2008, 18:89-102.
93. Ebert MS, Neilson JR and Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007, 4:721-726.
94. Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q and Deiters A. Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl 2008, 47:7482-7484.
95. Qin W, Zhao B, Shi Y, Yao C, Jin L and Jin Y. BMPRII is a direct target of miR-21. Acta Biochim Biophys Sin 2009, 41:618-623.
96. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N and Bacallado SA, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008, 26:561-569.
97. De Guire V, Caron M, Scott N, Ménard C, Gaumont-Leclerc MF, Chartrand P and Major F, et al. Designing small multiple-target artificial RNAs. Nucleic Acids Res 2010, 38:e140.
98. Budhu A, Ji J and Wang XW. The clinical potential of microRNAs. J Hematol Oncol 2010, 3:37.
99. Chan E, Prado DE and Weidhaas JB. Cancer microRNAs: From subtype profiling to predictors of response to therapy. Trends Mol Med 2011, 17:235-243.
100. Li Y, Yang X, Su LJ and Flaig TW. VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells. Oncol Rep 2010, 24:1019-1028.
101. Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW and Rothenberg SM, et al. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest 2011, 121:809-820.
102. Li CW, Shi L, Zhang KK, Li TY, Lin ZB, Lim MK and McKeon F, et al. Role of p63/p73 in epithelial remodeling and their response to steroid treatment in nasal polyposis. J Allergy Clin Immunol 2011, 127:765-772.
103. Tyagi S, Bhui K, Singh R, Singh M, Raisuddin S and Shukla Y. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73a in p53 mutant human epidermoid squamous carcinoma cells. Biochem Pharmacol 2010, 80:1326-1334.
104. Lunghi P, Costanzo A, Mazzera L, Rizzoli V, Levrero M and Bonati A. The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. Clin Cancer Res 2009, 15:6495-6502.
105. Zenvirt S, Kravchenko-Balasha N and Levitzki A. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents. Oncogene 2010, 29:6149-6159.
106. García-Escudero R, Martínez-Cruz AB, Santos M, Lorz C, Segrelles C, Garaulet G and Saiz-Ladera C, et al. Gene expression profiling of mouse p53-deficient epidermal carcinoma defines molecular determinants of human cancer malignancy. Mol Cancer 2010, 9:193.
107. Aigner A. MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. J Mol Med 2011, 89:445-57.
108. Gentner B, Schira G, Giustacchini A, Amendola M, Brown BD, Ponzoni M and Naldini L. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods 2009, 6:63-66.
109. Wang Z. The guideline of the design and validation of MiRNA mimics. Methods Mol Biol 2011, 676:211-223.
110. Bader AG, Brown D and Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010, 70:7027-7030.